ArticleArchives of disease in childhood2006
Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome.
Article in Archives of disease in childhood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Trial
- Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2009Trial
- A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Mechanisms of Podocyte Injury in Kidney Allografts.Kidney360 · 2026Review
- Factors associated with chronic calcineurin inhibitor nephrotoxicity in children with minimal-change disease.Renal failure · 2025Article
- Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Adult survivors of childhood-onset steroid-dependent and steroid-resistant nephrotic syndrome treated with cyclosporine: a long-term single-center experience.Pediatric nephrology (Berlin, Germany) · 2024Article
- Cyclosporine A CClinical and experimental nephrology · 2022Article
- Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.Indian pediatrics · 2021Article
- Current understandings in treating children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Review
- Efficacy of once-daily cyclosporine in Japanese children with steroid-dependent minimal change nephrotic syndrome.Clinical and experimental nephrology · 2021Article
- Role of Tacrolimus C/D Ratio in the First Year After Pediatric Liver Transplantation.Frontiers in pediatrics · 2021Article
- Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy.Clinical and experimental nephrology · 2018Article
- Calcineurin inhibitors and nephrotoxicity in children.World journal of pediatrics : WJP · 2018Review
- Impact of interrupted cyclosporine treatment on the development of chronic nephrotoxicity in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017Article
- Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment.Pediatric nephrology (Berlin, Germany) · 2017Article
- Predictive risk factors of steroid dependent nephrotic syndrome in children.Journal of nephropathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclosporine A (CsA) has been widely used in children with steroid dependent and steroid resistant nephrotic syndrome (NS) because of its efficacy in relieving these patients from systemic side effects of steroids. However, its long term use is controversial, since chronic CsA induced nephropathy (CsAN) may develop in a considerable number of patients. AIMS AND
methodsIn order to clarify the risk factors for the development of CsAN, the clinical characteristics of children with steroid dependent or steroid resistant NS taking CsA (target blood trough levels 50-150 ng/ml) for more than six months, managed at a single centre, were retrospectively analysed.
resultsThirteen of 30 children (24 boys and 6 girls) taking CsA (mean duration 43 months, range 6-144) had CsAN defined as the presence of CsA associated arteriopathy with or without striped tubulointerstitial lesions. The multivariate analysis revealed that CsA treatment for more than 36 months and an age younger than 5 years at the start of CsA treatment were independent risk factors for the development of CsAN. The univariate analysis also showed that patients with CsAN had more frequent relapses during CsA treatment than those without CsAN.
conclusionAn alternative treatment should be seriously considered after a 36 month administration of CsA in order to prevent CsAN. Data also suggest that CsA treatment in children younger than 5 years should be avoided if possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.